Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

CABTREO

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

Standard Dose
0.15%;3.1%;1.2%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CABTREO is listed in Drugs@FDA under application 216632 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE Form and strength GEL;TOPICAL - 0.15%;3.1%;1.2% Sponsor BAUSCH Submission history Latest submission status date: 2023-10-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview CABTREO is listed in Drugs@FDA under application 216632 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE Form and strength GEL;TOPICAL - 0.15%;3.1%;1.2% Sponsor BAUSCH Submission history Latest submission status date: 2023-10-20 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.